The Official Positions of the International Society for Clinical Densitometry: Indications of Use and Reporting of DXA for Body Composition

Journal of Clinical Densitometry

Volumn 16, Issue 4, 2013, Pages 496-507

  Kendler, David L ^a   Borges, Joao L C ^b   Fielding, Roger A ^c   Itabashi, Akira ^d   Krueger, Diane ^e   Mulligan, Kathleen ^f   Camargos, Bruno M ^g   Sabowitz, Brian ^d   Wu, Chih Hsing ^h   Yu, Elaine W ⁱ   Shepherd, John ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^c TUFTS UNIVERSITY   (United States)

^d University of Wisconsin ^*

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Hospital Mater Dei   (Brazil)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Body composition; DXA; Obesity; Sarcopenia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BARIUM; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; GADOLINIUM; INTEGRASE INHIBITOR; IODINATED CONTRAST MEDIUM; METFORMIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TESAMORELIN; ZIDOVUDINE;

ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; BARIATRIC SURGERY; BISPECTRAL INDEX; BODY COMPOSITION; BONE DENSITOMETRY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG MONITORING; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEAN BODY WEIGHT; LIPID COMPOSITION; LIPOATROPHY; LIPODYSTROPHY; MEASUREMENT ACCURACY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SARCOPENIA;

BODY COMPOSITION; DXA; OBESITY; SARCOPENIA;

ABSORPTIOMETRY, PHOTON; ALGORITHMS; BODY COMPOSITION; BONE DENSITY; CONGRESSES AS TOPIC; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84887015622     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2013.08.020     Document Type: Article

References (137)

1. Olbers T., Bjorkman S., Lindroos A., et al. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg 2006, 244(5):715-722.
2. Bredella M.A., Ghomi R.H., Thomas B.J., et al. Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa. Obesity (Silver Spring) 2010, 18(11):2227-2233.
3. Bridge P., Pocock N.A., Nguyen T., et al. Validation of longitudinal DXA changes in body composition from pre- to mid-adolescence using MRI as reference. J Clin Densitom 2011, 14(3):340-347.
4. Scherzer R., Shen W., Bacchetti P., et al. Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. Am J Clin Nutr 2008, 88(4):1088-1096.
5. Fakhrawi D.H., Beeson L., Libanati C., et al. Comparison of body composition by bioelectrical impedance and dual-energy x-ray absorptiometry in overweight/obese postmenopausal women. J Clin Densitom 2009, 12(2):238-244.
6. Xu L., Cheng X., Wang J., et al. Comparisons of body-composition prediction accuracy: a study of 2 bioelectric impedance consumer devices in healthy Chinese persons using DXA and MRI as criteria methods. J Clin Densitom 2011, 14(4):458-464.
7. Lustgarten M.S., Fielding R.A. Assessment of analytical methods used to measure changes in body composition in the elderly and recommendations for their use in phase II clinical trials. J Nutr Health Aging 2011, 15(5):368-375.
8. Di Sebastiano K.M., Mourtzakis M. A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer. Appl Physiol Nutr Metab 2012, 37(5):811-821.
9. Woodrow G. Body composition analysis techniques in the aged adult: indications and limitations. Curr Opin Clin Nutr Metab Care 2009, 12(1):8-14.
10. Park Y.W., Heymsfield S.B., Gallagher D. Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass?. Int J Obes Relat Metab Disord 2002, 26(7):978-983.
11. Kaul S., Rothney M.P., Peters D.M., et al. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring) 2012, 20(6):1313-1318. [Erratum appears in Obesity (Silver Spring). 2012;20(7):1544].
12. Micklesfield L.K., Goedecke J.H., Punyanitya M., et al. Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat. Obesity (Silver Spring) 2012, 20(5):1109-1114.
13. Mattsson S., Thomas B.J. Development of methods for body composition studies. Phys Med Biol 2006, 51(13):R203-R228.
14. Matthie J., Zarowitz B., De Lorenzo A., et al. Analytic assessment of the various bioimpedance methods used to estimate body water. J Appl Physiol 1998, 84(5):1801-1816.
15. Yamada Y., Schoeller D.A., Nakamura E., et al. Extracellular water may mask actual muscle atrophy during aging. J Gerontol A Biol Sci Med Sci 2010, 65(5):510-516.
16. Wagner D.R., Heyward V.H. Techniques of body composition assessment: a review of laboratory and field methods. Res Q Exerc Sport 1999, 70(2):135-149.
17. Ackland T.R., Lohman T.G., Sundgot-Borgen J., et al. Current status of body composition assessment in sport: review and position statement on behalf of the ad hoc research working group on body composition health and performance, under the auspices of the I.O.C. Medical Commission. Sports Med 2012, 42(3):227-249.
18. Vrouenraets S.M., Wit F.W., Garcia E.F., et al. Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV Clin Trials 2012, 13(2):103-110.
19. Dube M.P., Komarow L., Mulligan K., et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007, 45(5):508-514.
20. Yang Y., Wilder-Smith A., Panchalingam A., et al. Changes in body fat measured by DEXA in patients taking different formulations of stavudine. HIV Clin Trials 2005, 6(6):337-343.
21. Dube M.P., Parker R.A., Tebas P., et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005, 19(16):1807-1818.
22. McComsey G.A., Kitch D., Sax P.E., et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011, 53(2):185-196.
23. Mulligan K., Parker R.A., Komarow L., et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006, 41(5):590-597.
24. Moyle G.J., Andrade-Villanueva J., Girard P.M., et al. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther 2012, 17(4):689-700.
25. Curran A., Martinez E., Podzamczer D., et al. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial. Antivir Ther 2012, 17(4):711-718.
26. Negredo E., Miro O., Rodriguez-Santiago B., et al. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009, 49(6):892-900.
27. Ananworanich J., Nuesch R., Cote H.C.F., et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine-a Staccato trial substudy. J Antimicrob Chemother 2008, 61(6):1340-1343.
28. Martin A., Smith D., Carr A., et al. Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study). HIV Clin Trials 2004, 5(4):192-200.
29. Moyle G.J., Baldwin C., Langroudi B., et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003, 33(1):22-28.
30. Carr A., Workman C., Smith D.E., et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002, 288(2):207-215.
31. Martinez E., Visnegarwala F., Grund B., et al. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. AIDS 2010, 24(3):353-363.
32. Cooper D.A., Cordery D.V., Reiss P., et al. The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. HIV Med 2011, 12(1):31-39.
33. Hammond E., McKinnon E., Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010, 51(5):591-599.
34. Guaraldi G., Orlando G., Squillace N., et al. Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV Clin Trials 2006, 7(3):97-106.
35. Falutz J., Allas S., Blot K., et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007, 357(23):2359-2370.
36. Falutz J., Potvin D., Mamputu J.-C., et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010, 53(3):311-322.
37. Grunfeld C., Thompson M., Brown S.J., et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007, 45(3):286-297.
38. Kotler D.P., Muurahainen N., Grunfeld C., et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004, 35(3):239-252. [Erratum appears in J Acquir Immune Defic Syndr. 2006;43(3):381], [Erratum for J Acquir Immune Defic Syndr. 2006;43(3):378-80; PMID: 17079997].
39. Macallan D.C., Baldwin C., Mandalia S., et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 2008, 9(4):254-268.
40. Hadigan C., Yawetz S., Thomas A., et al. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004, 140(10):786-794.
41. Carr A., Workman C., Carey D., et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004, 363(9407):429-438.
42. Mulligan K., Yang Y., Wininger D.A., et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 2007, 21(1):47-57.
43. Slama L., Lanoy E., Valantin M.-A., et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 2008, 13(1):67-76.
44. Cavalcanti R.B., Raboud J., Shen S., et al. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 2007, 195(12):1754-1761.
45. Kohli R., Shevitz A., Gorbach S., Wanke C. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med 2007, 8(7):420-426.
46. Calmy A., Bloch M., Wand H., et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 2010, 11(8):493-501.
47. Bhasin S., Parker R.A., Sattler F., et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab 2007, 92(3):1049-1057.
48. Smith D.E., Hudson J., Martin A., et al. Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy. HIV Clin Trials 2003, 4(1):45-49.
49. Cavalcanti R.B., Cheung A.M., Raboud J., Walmsley S. Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research. J Clin Densitom 2005, 8(3):293-297.
50. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12(7):F51-F58.
51. Lo J.C., Mulligan K., Tai V.W., et al. "Buffalo hump" in men with HIV-1 infection. Lancet 1998, 351(9106):867-870.
52. Mulligan K., Tai V.W., Algren H., et al. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2001, 26(5):443-448.
53. Vigano A., Mora S., Testolin C., et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003, 32(5):482-489.
54. Brambilla P., Bricalli D., Sala N., et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001, 15(18):2415-2422.
55. Melvin A.J., Lennon S., Mohan K.M., Purnell J.Q. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses 2001, 17(12):1117-1123.
56. Carr A., Emery S., Law M., et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003, 361(9359):726-735.
57. Chaston T.B., Dixon J.B., O'Brien P.E. Changes in fat-free mass during significant weight loss: a systematic review. Int J Obes (Lond) 2007, 31(5):743-750.
58. Bales C.W., Buhr G. Is obesity bad for older persons? A systematic review of the pros and cons of weight reduction in later life. J Am Med Dir Assoc 2008, 9(5):302-312.
59. Waters D.L., Ward A.L., Villareal D.T. Weight loss in obese adults 65 years and older: a review of the controversy. Exp Gerontol 2013, 48(10):1054-1061.
60. Dixon J.B., Strauss B.J.G., Laurie C., O'Brien P.E. Changes in body composition with weight loss: obese subjects randomized to surgical and medical programs. Obesity (Silver Spring) 2007, 15(5):1187-1198.
61. Vatier C., Henegar C., Ciangura C., et al. Dynamic relations between sedentary behavior, physical activity, and body composition after bariatric surgery. Obes Surg 2012, 22(8):1251-1256.
62. Clements R.H., Saraf N., Kakade M., et al. Nutritional effectof oral supplement enriched in beta-hydroxy-beta-methylbutyrate, glutamine and arginine on resting metabolic rate after laparoscopic gastric bypass. Surg Endosc 2011, 25(5):1376-1382.
63. Ciangura C., Bouillot J.-L., Lloret-Linares C., et al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. Obesity (Silver Spring) 2010, 18(4):760-765.
64. Andreu A., Moize V., Rodriguez L., et al. Protein intake, body composition, and protein status following bariatric surgery. Obes Surg 2012, 20(11):1509-1515.
65. Tamboli R.A., Hossain H.A., Marks P.A., et al. Body composition and energy metabolism following Roux-en-Y gastric bypass surgery. Obesity (Silver Spring) 2010, 18(9):1718-1724.
66. Carrasco F., Ruz M., Rojas P., et al. Changes in bone mineral density, body composition and adiponectin levels in morbidly obese patients after bariatric surgery. Obes Surg 2009, 19(1):41-46.
67. Levitt D.G., Beckman L.M., Mager J.R., et al. Comparison of DXA and water measurements of body fat following gastric bypass surgery and a physiological model of body water, fat, and muscle composition. J Appl Physiol 2010, 109(3):786-795.
68. Giusti V., Suter M., Heraief E., et al. Effects of laparoscopic gastric banding on body composition, metabolic profile and nutritional status of obese women: 12-months follow-up. Obes Surg 2004, 14(2):239-245.
69. Coupaye M., Bouillot J.-L., Coussieu C., et al. One-year changes in energy expenditure and serum leptin following adjustable gastric banding in obese women. Obes Surg 2005, 15(6):827-833.
70. Coupaye M., Bouillot J.-L., Poitou C., et al. Is lean body mass decreased after obesity treatment by adjustable gastric banding?. Obes Surg 2007, 17(4):427-433.
71. Inge T., Wilson K.A., Gamm K., et al. Preferential loss of central (trunk) adiposity in adolescents and young adults after laparoscopic gastric bypass. Surg Obes Relat Dis 2007, 3(2):153-158.
72. Strauss B.J.G., Marks S.J., Growcott J.P., et al. Body composition changes following laparoscopic gastric banding for morbid obesity. Acta Diabetol 2003, 40(1 Suppl):S266-S269.
73. Sergi G., Lupoli L., Busetto L., et al. Changes in fluid compartments and body composition in obese women after weight loss induced by gastric banding. Ann Nutr Metab 2003, 47(3-4):152-157.
74. Villareal D.T., Chode S., Parimi N., et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011, 364(13):1218-1229.
75. Frimel T.N., Sinacore D.R., Villareal D.T. Exercise attenuates the weight-loss-induced reduction in muscle mass in frail obese older adults. Med Sci Sports Exerc 2008, 40(7):1213-1219.
76. Shah K., Stufflebam A., Hilton T.N., et al. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009, 17(12):2162-2168.
77. Janssen I., Ross R. Effects of sex on the change in visceral, subcutaneous adipose tissue and skeletal muscle in response to weight loss. Int J Obes Relat Metab Disord 1999, 23(10):1035-1046.
78. Rice B., Janssen I., Hudson R., Ross R. Effects of aerobic or resistance exercise and/or diet on glucose tolerance and plasma insulin levels in obese men. Diabetes Care 1999, 22(5):684-691.
79. Janssen I., Fortier A., Hudson R., Ross R. Effects of an energy-restrictive diet with or without exercise on abdominal fat, intermuscular fat, and metabolic risk factors in obese women. Diabetes Care 2002, 25(3):431-438.
80. Coates P.S., Fernstrom J.D., Fernstrom M.H., et al. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab 2004, 89(3):1061-1065.
81. Johnson J.M., Maher J.W., Samuel I., et al. Effects of gastric bypass procedures on bone mineral density, calcium, parathyroid hormone, and vitamin D. J Gastrointest Surg 2005, 9(8):1106-1110. discussion 1110-1.
82. Fleischer J., Stein E.M., Bessler M., et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab 2008, 93(10):3735-3740.
83. Anonymous Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003, 921:1-164. [back cover].
84. Knapp K.M., Welsman J.R., Hopkins S.J., et al. Obesity increases precision errors in dual-energy X-ray absorptiometry measurements. J Clin Densitom 2012, 15(3):315-319.
85. Yu E.W., Thomas B.J., Brown J.K., Finkelstein J.S. Simulated increases in body fat and errors in bone mineral density measurements by DXA and QCT. J Bone Miner Res 2012, 27(1):119-124.
86. Tothill P., Hannan W.J., Wilkinson S. Comparisons between a pencil beam and two fan beam dual energy X-ray absorptiometers used for measuring total body bone and soft tissue. Br J Radiol 2001, 74(878):166-176.
87. Glickman S.G., Marn C.S., Supiano M.A., Dengel D.R. Validity and reliability of dual-energy X-ray absorptiometry for the assessment of abdominal adiposity. J Appl Physiol 2004, 97(2):509-514.
88. Kim S.-H., Kim T.-H., Hwang H.-J. The relationship of physical activity (PA) and walking with sarcopenia in Korean males aged 60 years and older using the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV-2, 3), 2008-2009. Arch Gerontol Geriatr 2013, 56(3):472-477.
89. Bouchard D.R., Dionne I.J., Brochu M. Sarcopenic/obesity and physical capacity in older men and women: data from the Nutrition as a Determinant of Successful Aging (NuAge)-the Quebec longitudinal Study. Obesity (Silver Spring) 2009, 17(11):2082-2088.
90. Dufour A.B., Hannan M.T., Murabito J.M., et al. Sarcopenia definitions considering body size and fat mass are associated with mobility limitations: the Framingham Study. J Gerontol A Biol Sci Med Sci 2013, 68(2):168-174.
91. Patil R., Uusi-Rasi K., Pasanen M., et al. Sarcopenia and osteopenia among 70-80-year-old home-dwelling Finnish women: prevalence and association with functional performance. Osteoporos Int 2013, 24(3):787-796.
92. Koster A., Ding J., Stenholm S., et al. Does the amount of fat mass predict age-related loss of lean mass, muscle strength, and muscle quality in older adults?. J Gerontol A Biol Sci Med Sci 2011, 66(8):888-895.
93. Auyeung T.W., Lee J.S.W., Leung J., et al. Adiposity to muscle ratio predicts incident physical limitation in a cohort of 3,153 older adults-an alternative measurement of sarcopenia and sarcopenic obesity. Age 2012, 35(4):1377-1385.
94. Lee C.G., Boyko E.J., Strotmeyer E.S., et al. Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. J Am Geriatr Soc 2011, 59(7):1217-1224.
95. Levine M.E., Crimmins E.M. The impact of insulin resistance and inflammation on the association between sarcopenic obesity and physical functioning. Obesity (Silver Spring) 2012, 20(10):2101-2106.
96. Sanada K., Iemitsu M., Murakami H., et al. Adverse effects of coexistence of sarcopenia and metabolic syndrome in Japanese women. Eur J Clin Nutr 2012, 66(10):1093-1098.
97. Kim N.H., Kim H.S., Eun C.R., et al. Depression is associated with sarcopenia, not central obesity, in elderly Korean men. J Am Geriatr Soc 2011, 59(11):2062-2068.
98. Borel A.-L., Nazare J.-A., Smith J., et al. Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program. Obesity (Silver Spring) 2012, 20(6):1223-1233.
99. Shah N.R., Braverman E.R. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PLoS One 2012, 7(4):e33308. [Electronic Resource].
100. Rothney M.P., Catapano A.L., Xia J., et al. Abdominal visceral fat measurement using dual-energy X-ray: association with cardiometabolic risk factors. Obesity (Silver Spring) 2012, Dec 12. [Epub ahead of print].
101. Rothney M.P., Xia Y., Wacker W.K., et al. Precision of a new tool to measure visceral adipose tissue (VAT) using dual-energy X-Ray absorptiometry (DXA). Obesity (Silver Spring) 2013, 21(1):E134-E136.
102. Ergun D.L., Rothney M.P., Oates M.K., et al. Visceral adipose tissue quantification using lunar prodigy. J Clin Densitom 2013, 16(1):75-78.
103. Karelis A.D., Rabasa-Lhoret R., Pompilus R., et al. Relationship between the Bertin index to estimate visceral adipose tissue from dual-energy X-ray absorptiometry and cardiometabolic risk factors before and after weight loss. Obesity (Silver Spring) 2012, 20(4):886-890.
104. Zalesin K.C., Franklin B.A., Lillystone M.A., et al. Differential loss of fat and lean mass in the morbidly obese after bariatric surgery. Metab Syndr Relat Disord 2010, 8(1):15-20.
105. Winters-Stone K.M., Dobek J., Nail L.M., et al. Impact + resistance training improves bone health and body composition in prematurely menopausal breast cancer survivors: a randomized controlled trial. Osteoporos Int 2012, 24(5):1637-1646.
106. Josse A.R., Atkinson S.A., Tarnopolsky M.A., Phillips S.M. Increased consumption of dairy foods and protein during diet- and exercise-induced weight loss promotes fat mass loss and lean mass gain in overweight and obese premenopausal women. J Nutr 2011, 141(9):1626-1634.
107. Hull H., He Q., Thornton J., et al. iDXA, prodigy, and DPXL dual-energy X-ray absorptiometry whole-body scans: a cross-calibration study. J Clin Densitom 2009, 12(1):95-102.
108. Ioannou C., Javaid M.K., Mahon P., et al. The effect of maternal vitamin D concentration on fetal bone. J Clin Endocrinol Metab 2012, 97(11):E2070-E2077.
109. Azocar M.A., Cano F.J., Marin V., et al. Body composition in children on peritoneal dialysis. Adv Perit Dial 2004, 20:231-236.
110. Fields D.A., Demerath E.W. Relationship of insulin, glucose, leptin, IL-6 and TNF in human breast milk with infant growth and body composition. Pediatr Obes 2012, 7(4):304-312.
111. Crozier S.R., Harvey N.C., Inskip H.M., et al. Maternal vitamin D status in pregnancy is associated with adiposity in the offspring: findings from the Southampton Women's Survey. Am J Clin Nutr 2012, 96(1):57-63.
112. Bacha F., Gungor N., Lee S., Arslanian S.A. Type 2 diabetes in youth: are there racial differences in cell responsiveness relative to insulin sensitivity?. Pediatr Diabetes 2012, 13(3):259-265.
113. Libber J., Binkley N., Krueger D. Clinical observations in total body DXA: technical aspects of positioning and analysis. J Clin Densitom 2012, 15(3):282-289.
114. Ryder K.M., Shorr R.I., Tylavsky F.A., et al. Correlates of use of antifracture therapy in older women with low bone mineral density. J Gen Intern Med 2006, 21(6):636-641.
115. Nielsen T.L., Hagen C., Wraae K., et al. The impact of the CAG repeat polymorphism of the androgen receptor gene on muscle and adipose tissues in 20-29-year-old Danish men: Odense Androgen Study. Eur J Endocrinol 2010, 162(4):795-804.
116. Clark R.R., Bartok C., Sullivan J.C., Schoeller D.A. Is leg-to-leg BIA valid for predicting minimum weight in wrestlers?. Med Sci Sports Exerc 2005, 37(6):1061-1068.
117. Gallagher D., Heymsfield S.B., Heo M., et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000, 72(3):694-701.
118. Vikram N.K., Bhatt S.P., Bhushan B., et al. Associations of -308G/A polymorphism of tumor necrosis factor (TNF)-gene and serum TNF levels with measures of obesity, intra-abdominal and subcutaneous abdominal fat, subclinical inflammation and insulin resistance in Asian Indians in north India. Dis Markers 2011, 31(1):39-46.
119. Van Pelt R.E., Jankowski C.M., Gozansky W.S., et al. Sex differences in the association of thigh fat and metabolic risk in older adults. Obesity (Silver Spring) 2011, 19(2):422-428.
120. El-Maouche D., Xu X., Cofrancesco J., et al. Prevalence of low bone mineral density in a low-income inner-city population. J Bone Miner Res 2011, 26(2):388-396.
121. Jebb S.A., Osborne R.J., Dixon A.K., et al. Measurements of resting energy expenditure and body composition before and after treatment of small cell lung cancer. Ann Oncol 1994, 5(10):915-919.
122. Mourtzakis M., Prado C.M., Lieffers J.R., et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008, 33(5):997-1006.
123. Johnson R.K., Hildreth H.G., Contompasis S.H., Goran M.I. Total energy expenditure in adults with cerebral palsy as assessed by doubly labeled water. J Am Diet Assoc 1997, 97(9):966-970.
124. Sode-Carlsen R., Farholt S., Rabben K.F., et al. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome. Growth Horm IGF Res 2011, 21(4):185-190.
125. Fontana L., Villareal D.T., Weiss E.P., et al. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am J Physiol Endocrinol Metab 2007, 293(1):E197-E202.
126. Aubertin-Leheudre M., Lord C., Goulet E.D., et al. Effect of sarcopenia on cardiovascular disease risk factors in obese postmenopausal women. Obesity (Silver Spring) 2006, 14(12):2277-2283.
127. Engelen M.P., Schols A.M., Heidendal G.A., Wouters E.F. Dual-energy X-ray absorptiometry in the clinical evaluation of body composition and bone mineral density in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 1998, 68(6):1298-1303.
128. McCollough C.H., Schueler B.A., Atwell T.D., et al. Radiation exposure and pregnancy: when should we be concerned?. Radiographics 2007, 27(4):909-917. discussion 917-8.
129. Discovery Series FAQs 2013, Hologic, Accessed February 20, 2013. http://www.hologic.com/data/ProductSupport/Densitometry/Discovery/FAQs/Discovery-FAQ.pdf.
130. GEHealthcare-iDXA-Advance-Package-ProductSpec 2013, GEHealthcare, Accessed February 20, 2013. http://www3.gehealthcare.com/en/Products/Categories/Metabolic_Health/DXA_for_Metabolic_Health/~/media/Downloads/us/Product/Product-Categories/Metabolic-Health/Lunar-iDXA-for-Metabolic-Health/GEHealthcare-iDXA-Advance-Package-ProductSpec.pdf.
131. Jacobson J.A., Jamadar D.A., Hayes C.W. Dual X-ray absorptiometry: recognizing image artifacts and pathology. AJR Am J Roentgenol 2000, 174(6):1699-1705.
132. Sala A., Webber C., Halton J., et al. Effect of diagnostic radioisotopes and radiographic contrast media on measurements of lumbar spine bone mineral density and body composition by dual-energy x-ray absorptiometry. J Clin Densitom 2006, 9(1):91-96.
133. Chan P.S., Binkley N.C., Lalande B.M., et al. Artifactual reduction in bone density as a result of technetium-99m MDP for bone scanning: report of two cases. J Clin Densitom 2004, 7(4):457-458.
134. McKiernan F.E., Hocking J., Cournoyer S. Antecedent 99mTc-MDP and 99mTc-sestamibi administration corrupts bone mineral density measured by DXA. J Clin Densitom 2006, 9(2):164-166.
135. Gumuser G., Parlak Y., Topal G., et al. Effects of 99mTc-MIBI and 99mTc-MDP administration on dual-energy X-ray absorptiometry bone mineral density measurements. Nucl Med Commun 2009, 30(6):445-448.
136. Campbell A., McCarthy M., Blake M., Roff G. Effect of99mTc-MDP administration on dual-energy X-ray absorptiometry bone mineral density measurements. J Clin Densitom 2005, 8(1):14-17.
137. Mueller B., O'Connor M.K. Effects of radioisotopes on the accuracy of dual-energy X-ray absorptiometry for bone densitometry. J Clin Densitom 2002, 5(3):283-287.